Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma by Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Debra Jamison, Dan Sageser, Joanne Jeter, Tawnya L. Bowles, Donald M. Cannon, Ben Haaland, Joyce D. Schroeder, David A. Nix, Aaron Atkinson, John Hyngstrom, Jordan McPherson, Aik-Choon Tan, Siwen Hu-Lieskovan

Get full text

Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Result... by Spencer G. Van Decar, Elizabeth L. Carpenter, Alexandra M. Adams, Robert C. Chick, Guy T. Clifton, Alex Stojadinovic, Timothy J. Vreeland, Franklin A. Valdera, Ankur Tiwari, Anne E. O'Shea, Patrick M. McCarthy, Diane F. Hale, Phillip M Kemp Bohan, Annelies T. Hickerson, Jessica L. Cindass, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Xianzhong Yu, Thomas Wagner, Mark B. Faries, George E. Peoples

Get full text